Preclinical combination therapy of the investigational drug NAMI-A+ with doxorubicin for mammary cancer

Investigational New Drugs

Volumn 33, Issue 1, 2015, Pages 53-63

  Bergamo, Alberta ^a   Riedel, Tina ^b   Dyson, Paul J ^b   Sava, Gianni ^a,c  

^a Callerio Foundation   (Italy)

^b EPFL   (Switzerland)

^c UNIVERSITY OF TRIESTE   (Italy)

Author keywords

Combination therapy; Doxorubicin; In vitro; In vivo; Mammary cancer; NAMI A

Indexed keywords

ANTIMYCIN A1; AURANOFIN; CISPLATIN; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DOXORUBICIN; ESEROLINE; FLUOROURACIL; GEMCITABINE; IMIDAZOLIUM TRANS [TETRACHLORO[DIMETHYLSULFOXIDE][IMIDAZOLE]RUTHENATE (III)]; METHOTREXATE; MITOXANTRONE; PACLITAXEL; PODOPHYLLOTOXIN; RUTHENIUM COMPLEX; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DIMETHYL SULFOXIDE; IMIDAZOLIUM-BIS(IMIDAZOLE)DIMETHYLSULFOXIDEIMIDAZOTETRACHLORORUTHENATE(III); ORGANOMETALLIC COMPOUND; RUTHENIUM;

ANIMAL CELL; ARTICLE; BREAST CANCER; CANCER CELL LINE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER SURGERY; CANCER SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG ANTAGONISM; DRUG POTENTIATION; DRUG STRUCTURE; HIGH THROUGHPUT SCREENING; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIFE EXPECTANCY; LUNG METASTASIS; LUNG NODULE; MAXIMUM TOLERATED DOSE; METASTASIS POTENTIAL; MOUSE; MULTIPLE CYCLE TREATMENT; NON SMALL CELL LUNG CANCER; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; SIGNAL NOISE RATIO; SURVIVAL TIME; TRANSMISSION ELECTRON MICROSCOPY; TUMOR GROWTH; TUMOR NECROSIS; TUMOR VOLUME; ANALOGS AND DERIVATIVES; ANIMAL; CBA MOUSE; CELL SURVIVAL; DRUG EFFECTS; KIDNEY; LIVER; LUNG; LUNG NEOPLASMS; MAMMARY NEOPLASMS, ANIMAL; MCF 7 CELL LINE; METABOLISM; PATHOLOGY; SECONDARY;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL SURVIVAL; DIMETHYL SULFOXIDE; DOXORUBICIN; HUMANS; KIDNEY; LIVER; LUNG; LUNG NEOPLASMS; MAMMARY NEOPLASMS, ANIMAL; MCF-7 CELLS; MICE, INBRED CBA; ORGANOMETALLIC COMPOUNDS; RUTHENIUM;

EID: 84922081405     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-014-0175-5     Document Type: Article

References (42)

1. Bergamo A, Gaiddon C, Schellens JHM, Beijnen JH, Sava G (2012) Approaching tumour therapy beyond platinum drugs. Status of the art and perspectives of ruthenium drug candidates. J Inorg Biochem 106:90-99
2. Romero-Canelon I, Sadler PJ (2013) Next-generation metal anticancer complexes: multitargeting via redox modulation. Inorg Chem 52:12276-12291
3. Komeda S, Casini A (2012) Next-generation anticancer metallodrugs. Curr Top Med Chem 12:219-235
4. 4(DMSO)Im], a metal complex of ruthenium with antimetastatic properties. Clin Exp Metastasis 10:273-280
5. Sava G, Capozzi I, Clerici K, Gagliardi R, Alessio E, Mestroni G (1998) Pharmacological control of lung metastases of solid tumours by a novel ruthenium complex. Clin Exp Metastasis 16:371-379
6. Sava G, Zorzet S, Turrin C, Vita F, Soranzo MR, Cocchietto M, Bergamo A, DiGiovine S, Pezzoni G, Sartor L, Garbisa S (2003) Dual action of NAMI-A in inhibition of solid tumor metastasis: selective targeting of metastatic cells and binding to collagen. Clin Cancer Res 9:1898-1905
7. Sava G, Gagliardi R, Bergamo A, Alessio E, Mestroni G (1999) Treatment of metastases of solid mouse tumours by NAMI-A: comparison with cisplatin, cyclophosphamide and dacarbazine. Anticancer Res 19:969-972
8. Bergamo A, Gagliardi R, Scarcia V, Furlani A, Alessio E, Mestroni G, Sava G (1999) In vitro cell cycle arrest, in vivo action on solid metastasizing tumors, and host toxicity of the antimetastatic drug NAMI-A and cisplatin. J Pharmacol Exp Ther 289:559-564
9. Gava B, Zorzet S, Spessotto P, Cocchietto M, Sava G (2006) Inhibition of B16 melanoma metastases with the ruthenium complex imidazolium trans-imidazoledimethylsulfoxide-tetrachlororuthenate and down-regulation of tumor cell invasion. J Pharmacol Exp Ther 317:284-291
10. Bergamo A, Delfino R, Casarsa C, Sava G (2012) Hyperphosphorylation maintenance drives the time-course of G2-M cell cycle arrest after short treatment with NAMI-A in KB cells. Anti Cancer Agents Med Chem 12:949-958
11. Fisher B, Bauer M, Wickerham DL, Redmond CK, Fisher ER, Cruz AB, Foster R, Gardner B, Lerner H, Margolese R (1983) Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer: an NSABP update. Cancer 52:1551-1557
12. Kim T, Giuliano AE, Lyman GH (2006) Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. Cancer 106:4-16
13. Fontain DB, van de Water W, Mieog JS, Liefers GJ, van de Velde CJ (2013) Timing of the sentinel lymph node biopsy in breast cancer patients receiving neoadjuvant therapy - recommendations for clinical guidance. Eur J Surg Oncol 39:417-424
14. Adjuvant systemic therapy for women with node-positive breast cancer. The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. CMAJ 1998,158 Suppl 3:S52-64.
15. Rademaker-Lakhai JM, van den Bongard D, Pluim D, Beijnen JH, Schellens JH (2004) A Phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent. Clin Cancer Res 10:3717-3727
16. Leijen S. Phase I/II Study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy. In: Development of combination Therapy with anticancer drugs. PhD Thesis 2013, Gildeprint Drukkerijen, The Netherlands, pp. 274-336.
17. Gao G, Jiang J, Liang X, Zhou X, Huang R, Chu Z, Zhan Q (2009) A meta-analysis of platinum plus gemcitabine or vinorelbine in the treatment of advanced non-small-cell lung cancer. Lung Cancer 65:339-344
18. Clegg A, Scott DA, Sidhu M, Hewitson P, Waugh N (2001) A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer. Health Technol Assess 5:1-195
19. de Castria TB, da Silva EM, Gois AF, Riera R (2013) Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer. Cochrane Database Syst Rev 8:CD009256
20. Matsumoto M, Takeda Y, Maki H, Tojo K, Wada T, Nishitani Y, Maekawa R, Yoshioka T (2001) Preclinical in vivo antitumor efficacy of nedaplatin with gemcitabine against human lung cancer. Jpn J Cancer Res 92:51-58
21. Giovannetti E, Mey V, Nannizzi S, Barsanti G, Savarino G, Ricciardi S, Del Tacca M, Danesi R (2007) Cytotoxic activity of gemcitabine and correlation with expression profile of drug-related genes in human lymphoid cells. Pharmacol Res 55:343-349
22. Pacor S, Zorzet S, Cocchietto M, Bacac M, Vadori M, Turrin C, Gava B, Castellarin A, Sava G (2004) Intra-tumoral nami-a treatment triggers metastasis reduction, which correlates to cd44 regulation and til recruitment. J Pharmacol Exp Ther 310:737-744
23. 4(DMSO)Im], a novel selective antimetastatic agent, on the survival time of mice with P388 leukemia, P388/DDP subline and MCa mammary carcinoma. Metal-Based Drugs 2:195-199
24. Khalaila I, Bergamo A, Bussy F, Sava G, Dyson PJ (2006) The role of cisplatin and NAMI-A plasma-protein interactions in relation to combination therapy. Int J Oncol 29:261-268
25. Therasse P, Mauriac L, Welnicka-Jaskiewicz M, Bruning P, Cufer T, Bonnefoi H, Tomiak E, Prichard KI, Hamilton A, Piccart MJ (2003) Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide+filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study. J Clin Oncol 21:843-850
26. Mestroni G, Alessio E, Sava G. Nerw salts of anionic complexex of Ru(III), as antimetastatic and antineoplastic agents. PCT. C 07 F 15/00, A61K 31/28. WO 98/00431 08.01.98.
27. Zhang JH, Chung TD, Oldenburg KR (1999) A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 4:67-73
28. Mosman T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63
29. Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, Fine DL, Abbott BJ, Mayo JG, Shoemaker RH, Boyd MR (1988) Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 48:598-601
30. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzym Regul 22:27-55
31. Chou TC (1991) The median-effect principle and the combination index for quantitation of synergism and antagonism. In: Chou TC, Rideout DC (eds) Synergism and antagonism in chemotherapy. Academic, San Diego, pp 61-102
32. Chou TC, Tan QH, Sirontak FM (1993) Quantitation of the synergistic interaction of edatrexate and cisplatin in vitro. Cancer Chemother Pharmacol 31:259-264
33. Poliak-Blazi M, Boranic M, Marzan B, Radacic M (1981) A transplantable aplastic mammary carcinoma of CBA mice. Vet Arh 51:382-385
34. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, Double JA, Everitt J, Farningham DAH, Glennie MJ, Kelland LR, Robinson V, Stratford IJ, Tozer GM, Watson S, Wedge SR, Eccles SA (2010) Guidelines for the welfare and use of animals in cancer research. Br J Cancer 102:1555-1577
35. Rapozzi V, Zorzet S, Comelli M, Mavelli I, Perissin L, Giraldi T (1998) Melatonin decreases bone marrow and lymphatic toxicity of Adriamycin in mice bearing TLX5 lymphoma. Life Sci 63:1701-1713
36. Dethlefsen LA, Riley RM, Roti JL (1979) Flow cytometric analysis of adriamycin-perturbed mouse mammary tumors. J Histochem Cytochem 27:463-469
37. 4(DMSO)Im] after acute i.v. treatment in mice. Anticancer Res 20:197-202
38. Fornari FA, Randolph JK, Yalowich JC, Ritke MK, Gerwirtz DA (1994) Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells. Mol Pharmacol 45:649-656
39. Hudis C (1997) Sequential dose-dense adjuvant therapy with doxorubicin, paclitaxel and cyclophosphamide. Oncology 11:15-18
40. Mendes F, Groessl M, Nazarov AA, Tsybin YO, Sava G, Santos I (2011) PJ Dyson, Casini A. Metal-based inhibition of poly(ADP-ribose) polymerase - the guardian angel of DNA. J Med Chem 54:2196-2206
41. Kaun C, Zhang J, Honbo N, Kaileimer JS (2010) Doxorubicin cariomyopathy. Cardiology 115:155-160
42. Pillozzi Y, Stefanini S, Ristori M, D'Amico M, Alessio E, Scaletti F, Arcangeli A, Messori L. NAMI-A is highly cytotoxic toward various leukaemia cell lines. Angewandte Chemie Int Ed., 2014, in press.